LL
LLY.XETRA Eli Lilly and Company
- Market cap
- EUR 1.12T
- P/E
- 47.4x
- P/B
- 31.58x
- ROE
- 70.7%
- Dividend yield
- 0.49%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LLY.XETRA undervalued?
Graham numberThe Graham number of Eli Lilly and Company cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eli Lilly and Company fundamental analysis
No fundamental analysis for Eli Lilly and Company yet.
Eli Lilly and Company stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and…
Full company profileEli Lilly and Company financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Eli Lilly and Company annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 21.2B | 20.0B | 21.5B | 22.3B | 24.5B | 28.3B | 28.5B | 34.1B | 45.0B | 65.2B | 89.5B |
| Gross Profit | 15.5B | 15.5B | 16.8B | 17.6B | 19.1B | 21.0B | 21.9B | 27.0B | 36.6B | 54.6B | 75.1B |
| Operating Income | 3.87B | 4.25B | 6.03B | 6.00B | 7.21B | 7.93B | 8.65B | 10.8B | 17.5B | 29.7B | 43.7B |
| EBITDA | 5.06B | 4.10B | 5.53B | 6.90B | 8.91B | 8.04B | 8.66B | 8.57B | 15.2B | 31.7B | 49.6B |
| Net Income | 2.74B | -204M | 3.23B | 8.32B | 6.19B | 5.58B | 6.24B | 5.24B | 10.6B | 20.6B | 28.1B |
| EPS | 2.49 | -0.19 | 3.13 | 8.69 | 6.47 | 5.85 | 6.57 | 5.80 | 12 | 23 | 31 |
| Balance Sheet | |||||||||||
| Total Assets | 38.8B | 45.0B | 43.9B | 39.3B | 46.6B | 48.8B | 49.5B | 64.0B | 78.7B | 112B | 146B |
| Total Liabilities | 24.7B | 33.3B | 33.0B | 36.6B | 40.8B | 39.7B | 38.7B | 53.1B | 64.4B | 85.9B | 106B |
| Shareholders' Equity | 14.0B | 11.6B | 9.83B | 2.61B | 5.64B | 8.98B | 10.6B | 10.8B | 14.2B | 26.5B | 39.7B |
| Cash & Short-term Investments | 6.04B | 8.03B | 7.41B | 2.44B | 3.68B | 3.91B | 2.21B | 2.93B | 3.42B | 7.27B | 4.82B |
| Total Debt | 10.3B | 13.6B | 10.3B | 15.8B | 16.6B | 16.9B | 16.2B | 25.2B | 33.6B | 42.5B | 48.8B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 4.85B | 5.62B | 5.52B | 4.84B | 6.50B | 7.26B | 7.08B | 4.24B | 8.82B | 16.8B | 36.9B |
| Capital Expenditure | 1.09B | 2.16B | 3.02B | 1.35B | 2.03B | 1.87B | 2.48B | 7.39B | 8.40B | 10.8B | 15.7B |
| Free Cash Flow | 3.76B | 3.45B | 2.51B | 3.48B | 4.47B | 5.39B | 4.60B | -3.15B | 414M | 5.96B | 21.2B |
| Ratios | |||||||||||
| ROE | 19.5% | -1.8% | 32.9% | 319.1% | 109.8% | 62.2% | 58.6% | 48.6% | 74.6% | 77.8% | 70.7% |
| ROA | 7.1% | -0.5% | 7.4% | 21.2% | 13.3% | 11.4% | 12.6% | 8.2% | 13.5% | 18.4% | 19.2% |
| Net Profit Margin | 12.9% | -1.0% | 15.0% | 37.3% | 25.2% | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% | 31.4% |
| Debt to Equity | 0.74x | 1.18x | 1.05x | 6.06x | 2.94x | 1.88x | 1.52x | 2.34x | 2.37x | 1.60x | 1.23x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Eli Lilly and Company dividends
- Dividend yield
- 0.49%
- Forward dividend
- 6.18 EUR
- Payout ratio
- 26.1%
- Ex-dividend date
- Nov 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 5.38B | 5.99 | 26.1% |
| 2024 | USD 4.68B | 5.18 | 44.2% |
| 2023 | USD 4.07B | 4.51 | 77.7% |
| 2022 | USD 3.54B | 3.72 | 56.6% |
| 2021 | USD 3.09B | 3.24 | 55.3% |
| 2020 | USD 2.69B | 2.81 | 43.4% |
| 2019 | USD 2.41B | 2.52 | 29.0% |
| 2018 | USD 2.31B | 2.24 | 71.5% |
| 2017 | USD 2.19B | 2.08 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Eli Lilly and Company
- Insiders 0.16%
- Institutions 85.45%
- Public & others 14.39%
- Shares outstanding 891M
- Free float 888M
Eli Lilly and Company company profile
- Company name
- Eli Lilly and Company
- Ticker
- LLY.XETRA
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 50,000
- Fiscal year end
- December
- Address
- Lilly Corporate Center, Indianapolis, IN, United States, 46285
- Phone
- 317 276 2000
- Website
- lilly.com
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company management
10- Mr. David A. RicksChairman, President & CEO · born 1968
- Mr. Lucas E. MontarceExecutive VP & CFO · born 1977
- Dr. Daniel M. Skovronsky M.D., Ph.D.Chief Scientific & Product Officer and President of Lilly Research Laboratories · born 1973
- Ms. Anat Hakim J.D.Executive VP, General Counsel & Secretary · born 1969
- Mr. Jacob S. Van NaardenExecutive VP, President of Lilly Oncology & Head of Corporate Business Development · born 1985
- Mr. Donald A. ZakrowskiSenior VP of Finance & Chief Accounting Officer
- Mr. Diogo RauExecutive VP and Chief Information & Digital Officer · born 1975
- Mr. Michael CzaparSenior Vice President of Investor Relations
- Mr. Eric DozierExecutive VP & Chief People Officer · born 1967
- Mr. Ilya YuffaExecutive VP and President of Lilly USA & Global Customer Capabilities · born 1975